The economic burden of TNFα inhibitors and other biologic treatments in Norway

OBJECTIVE: Costly biologic therapies have improved function and quality of life for patients suffering from rheumatic and inflammatory bowel diseases. In this survey, we aimed to document and analyze the costs. METHODS: In 2008, the total costs of tumor necrosis factor alpha inhibitors and other bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Norum, Jan, Koldingsnes, Wenche, Aanes, Torfinn, Antonsen, Margaret Aarag, Florholmen, Jon, Kondo, Masahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169971/
https://www.ncbi.nlm.nih.gov/pubmed/21935335
http://dx.doi.org/10.2147/CEOR.S15988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169971/
https://www.ncbi.nlm.nih.gov/pubmed/21935335
http://dx.doi.org/10.2147/CEOR.S15988

Ejemplares similares